Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD) Clinical Trial

Official title:

A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04380142
• Other study ID #: M15-736
• Secondary ID: 2019-003930-18
• Status: Completed
• Phase: Phase 3
• Start date: October 19, 2020
• Est. completion date: September 29, 2021

Study information

• Verified date: October 2022
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study measures the efficacy, safety, and tolerability of ABBV-951 versus oral Levodopa (LD)/Carbidopa (CD) [LD/CD] in advanced PD participants to achieve reduction in motor fluctuations. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given subcutaneously (under the skin) for the treatment of Parkinson's Disease. Adult participants with advanced PD will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 80 sites across the world. In one arm, participants will receive ABBV-951 solution as a continuous infusion under the skin plus oral placebo capsules for LD/CD. In the second arm, participants will receive placebo solution for ABBV-951 as a continuous infusion under the skin plus oral capsules containing LD/CD tablets. The treatment duration is 12 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 174
• Est. completion date: September 29, 2021
• Est. primary completion date: September 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive.
• Participant must be taking a minimum of 400 milligrams/day (mg/day) of Levodopa (LD) equivalents and be judged by the investigator to have motor symptoms inadequately controlled by current therapy, have a recognizable/identifiable "Off" and "On" states (motor fluctuations), and have an average "Off" time of at least 2.5 hours/day over 3 consecutive PD Diary days with a minimum of 2 hours each day.
• Participant or caregiver, if applicable, demonstrates the understanding and correct use of the delivery system, including the insertion of the cannula into the participant's abdomen, as assessed by the investigator or designee during the Screening period.

Exclusion Criteria:

• Clinically significant, unstable medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.
• History of allergic reaction or significant sensitivity to LD or constituents of the study drug (and its excipients) and/or other products in the same class.
• Participant has not received deep brain stimulation, CD/LD enteral suspension, or any other PD medication as continuous daily infusion, whether commercially available or investigational. Previous exposure to ABBV-951 is not allowed.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease (PD)

Intervention

Drug:
• ABBV-951
Solution for continuous subcutaneous infusion (CSCI)
• Placebo for Levodopa/Carbidopa (LD/CD)
Oral capsule
• Levodopa/Carbidopa (LD/CD)
Oral encapsulated tablet
• Placebo for ABBV-951
Solution for continuous subcutaneous infusion (CSCI)

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital /ID# 216533	Adelaide	South Australia
Australia	Kingston Centre /ID# 216537	Cheltenham	Victoria
Australia	Liverpool Hospital /ID# 218681	Liverpool	New South Wales
Australia	The Royal Melbourne Hospital /ID# 216536	Parkville	Victoria
Australia	Gold coast University Hospital /ID# 218373	SouthPort	Queensland
Australia	Westmead Hospital /ID# 216535	Westmead	New South Wales
United States	Duplicate_Atlanta Center for Medical Res /ID# 217091	Atlanta	Georgia
United States	University of Colorado Hospital /ID# 216527	Aurora	Colorado
United States	University of Alabama at Birmingham - Main /ID# 216595	Birmingham	Alabama
United States	Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 216517	Boca Raton	Florida
United States	Alpine Clinical Research Center /ID# 216637	Boulder	Colorado
United States	St Elizabeth's Medical Center - Brighton /ID# 216716	Brighton	Massachusetts
United States	Clinical Research Professionals - Chesterfield /ID# 216669	Chesterfield	Missouri
United States	Rush University Medical Center /ID# 216567	Chicago	Illinois
United States	University of Chicago Medical /ID# 217187	Chicago	Illinois
United States	Ohio State University - Wexner Medical Center /ID# 216900	Columbus	Ohio
United States	Houston Pulmonary Sleep and Allergy Associates /ID# 216942	Cypress	Texas
United States	Kerwin Research Center /ID# 216587	Dallas	Texas
United States	Neurology Consultants of Dallas - LBJ Fwy /ID# 216564	Dallas	Texas
United States	Brain Matters Research /ID# 217089	Delray Beach	Florida
United States	Denver Neurological Research, LLC /ID# 216784	Denver	Colorado
United States	Michigan State University /ID# 217158	East Lansing	Michigan
United States	Rocky Mountain Movement Disorders Center /ID# 216737	Englewood	Colorado
United States	The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 216705	Fountain Valley	California
United States	KCA Neurology - Franklin /ID# 217419	Franklin	Tennessee
United States	Neuro Pain Medical Center /ID# 216551	Fresno	California
United States	Fixel Institute for Neurological Diseases /ID# 216514	Gainesville	Florida
United States	The Neurological Center of North Georgia /ID# 216499	Gainesville	Georgia
United States	Texas Movement Disorder Specialists /ID# 216523	Georgetown	Texas
United States	Prisma Health-Upstate /ID# 216594	Greenville	South Carolina
United States	Premier Neurology, P.C. /ID# 217308	Greer	South Carolina
United States	Houston Methodist Hospital /ID# 216707	Houston	Texas
United States	Indiana Clinical Research Cent /ID# 216615	Indianapolis	Indiana
United States	St. Luke's Hosp. of Kansas City /ID# 216633	Kansas City	Missouri
United States	Univ Kansas Med Ctr /ID# 216528	Kansas City	Kansas
United States	University of California, San /ID# 216598	La Jolla	California
United States	Northwell Health /ID# 216833	Lake Success	New York
United States	Global Neurosciences Institute /ID# 217875	Lawrenceville	New Jersey
United States	University of Arkansas for Medical Sciences /ID# 216501	Little Rock	Arkansas
United States	Loma Linda University Medical /ID# 216500	Loma Linda	California
United States	Collaborative Neuroscience Research - Long Beach /ID# 216970	Long Beach	California
United States	University of California, Los Angeles /ID# 216674	Los Angeles	California
United States	Visionary Investigators Network - Miami /ID# 216679	Miami	Florida
United States	Medical College of Wisconsin /ID# 216498	Milwaukee	Wisconsin
United States	University of South Alabama /ID# 216757	Mobile	Alabama
United States	Vanderbilt University Medical Center /ID# 216675	Nashville	Tennessee
United States	The Orthopedic Foundation /ID# 217157	New Albany	Ohio
United States	Mount Sinai Beth Israel /ID# 216712	New York	New York
United States	Christiana Care Health Service /ID# 216515	Newark	Delaware
United States	Meridian Clinical Research /ID# 216731	Norfolk	Virginia
United States	Renstar Medical Research /ID# 216765	Ocala	Florida
United States	Neurology Associates Ormond Beach /ID# 216521	Ormond Beach	Florida
United States	SC3 Research Group - Pasadena /ID# 216821	Pasadena	California
United States	Thomas Jefferson University Hospital /ID# 216553	Philadelphia	Pennsylvania
United States	University of Pennsylvania /ID# 216560	Philadelphia	Pennsylvania
United States	Barrow Neurological Institute /ID# 216566	Phoenix	Arizona
United States	HonorHealth /ID# 216642	Phoenix	Arizona
United States	Xenoscience, Inc /ID# 217110	Phoenix	Arizona
United States	Parkinson's Disease Treatment Center of Southwest Florida /ID# 222656	Port Charlotte	Florida
United States	Coastal Neurology /ID# 217190	Port Royal	South Carolina
United States	Legacy Research Institute /ID# 216558	Portland	Oregon
United States	Neurological Associates - Forest Ave /ID# 216636	Richmond	Virginia
United States	University of Rochester /ID# 218737	Rochester	New York
United States	Central Texas Neurology Consul /ID# 216629	Round Rock	Texas
United States	Washington University-School of Medicine /ID# 216548	Saint Louis	Missouri
United States	University of Utah Health Care /ID# 216710	Salt Lake City	Utah
United States	Movement Disorders Center of Arizona /ID# 216503	Scottsdale	Arizona
United States	Swedish Neuroscience /ID# 216526	Seattle	Washington
United States	Inland Northwest Research /ID# 221036	Spokane	Washington
United States	Banner Sun Health Res Inst /ID# 216507	Sun City	Arizona
United States	University of South Florida /ID# 216638	Tampa	Florida
United States	The Movement Disorder Clinic of Oklahoma /ID# 216860	Tulsa	Oklahoma
United States	Georgetown University Hospital /ID# 216632	Washington	District of Columbia
United States	Cedars-Sinai Medical Center-West Hollywood /ID# 216561	West Hollywood	California
United States	Premiere Research Institute - Palm Beach /ID# 217207	West Palm Beach	Florida
United States	Wake Forest Univ HS /ID# 216522	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia	"On" time is defined as periods of good motor symptom control, and was assessed by the Parkinson's Disease (PD) diary. The normalized "On" time without troublesome dyskinesia is the sum of the normalized "On" time without dyskinesia and the normalized "On" time with non-troublesome dyskinesia. "On" time without dyskinesia plus "On" time with non-troublesome dyskinesia are based on the PD Diary (normalized to a 16-hour waking day averaged over 3 consecutive days). Baseline value is defined as the average of normalized "On" time without troublesome dyskinesia collected over the 3 PD Diary days before randomization.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "Off" Time (Hours)	"Off" time is defined as periods of poor mobility, tremor, slowness, and stiffness and was assessed by the PD Diary.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score	The Part II MDS-UPDRS is an investigator-used rating tool to follow the longitudinal course of PD. MDS-UPDRS is multimodal scale assessing impairment and disability. Part II assesses the participant's motor experiences of daily living with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Early Morning "Off" Status (Morning Akinesia) at Week 12 of the Double-Blind Treatment Period	Early morning "Off" status is assessed by the PD Diary as percentage of participants with early morning "Off" upon waking up at Week 12, based on the first morning symptom upon awakening on the last valid PD Diary day at Week 12.; "Off" time is defined as periods of poor mobility, tremor, slowness, and stiffness and was assessed by the PD Diary.	Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Dyskinesia (Hours)	"On" time is defined as periods of good motor symptom control, and was assessed by the PD diary. The normalized "On" time without dyskinesia is defined as the hours of average daily normalized "On" time without dyskinesia as assessed by the PD Diary (normalized to a 16-hour waking day averaged over 3 consecutive days).; Baseline value is defined as the average of normalized "On" time without dyskinesia collected over the 3 PD Diary days before randomization.	Baseline, Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score	The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Higher scores indicate higher frequency and more severe impact of PD on sleep.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Quality of Life Assessed by Parkinson's Disease Questionnaire 39 Item (PDQ-39) Summary Index Score	The PDQ-39 is a disease-specific instrument designed to measure aspects of health that are relevant to participants with PD, and which may not be included in general health status questionnaires. It evaluates the 8 dimensions of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, and communication. Data from the PDQ-39 can be presented in either domain scores or as a summary index score. The full range of the PDQ-39 Summary Index score is from 0 (no patient-related symptoms/quality of life unaffected) to 100 (highest patient-related symptoms/low quality of life).	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Quality of Life Assessed by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Summary Index	The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. The health status is converted to an index value using the country-specific weighted scoring algorithm for the United States (US). The summary index value for the US ranges from a worst score of -0.109 to a best score of 1. An increase in the EQ-5D-5L total score indicates improvement.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Median Bradykinesia Score (BK50) as Assessed by the Parkinson's KinetiGraph/Personal KinetiGraph (PKG) Wearable Device	The PKG wearable device is an innovative mobile health technology that provides continuous, objective, ambulatory assessment of the symptoms of PD including tremor, bradykinesia, dyskinesia, and daytime somnolence. For each participant, the PKG watch collected data continuously and an algorithm calculated a bradykinesia score every 2 minutes between 9am-6pm across multiple days. Among these scores for this participant at this visit, the median of all the score values is defined as BK50. A higher score indicates worse bradykinesia (there is no prespecified range of scores). The BK50 scores for all participants across all visits were then analyzed with mixed-effect model for repeated measures (MMRM) and the LS mean (model-based mean) was obtained from the model.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Interquartile Range of Bradykinesia Score (BK75-BK25) as Assessed by the PKG Wearable Device	The PKG wearable device is an innovative mobile health technology that provides continuous, objective, ambulatory assessment of the symptoms of PD including tremor, bradykinesia, dyskinesia, and daytime somnolence. For each participant, the PKG watch collected data continuously and an algorithm calculated a bradykinesia score every 2 minutes between 9am-6pm across multiple days. Among these scores for this participant at this visit, the median of all the score values is defined as BK50 (there is no prespecified range of scores). BK75-BK25 is the difference between the third quartile (BK75) and first quartile (BK25) bradykinesia scores, and this interquartile range is a measure of variability of bradykinesia. A higher score indicates a higher degree of variability in bradykinesia scores. The BK75 and BK 25 scores for all participants across all visits were then analyzed with mixed-effect model for repeated measures (MMRM) and the LS mean (model-based mean) was obtained from the model.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Median Dyskinesia Score (DK50) as Assessed by the PKG Wearable Device	The PKG wearable device is an innovative mobile health technology that provides continuous, objective, ambulatory assessment of the symptoms of PD including tremor, bradykinesia, dyskinesia, and daytime somnolence. For each participant, the PKG watch collected data continuously and an algorithm calculated a dyskinesia score every 2 minutes between 9am-6pm across multiple days. Among these scores for this participant at this visit, the median of all the score values is defined as DK50. A higher score indicates worse dyskinesia (there is no prespecified range of scores). The DK50 scores for all participants across all visits were then analyzed with mixed-effect model for repeated measures (MMRM) and the LS mean (model-based mean) was obtained from the model.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Change From Baseline to Week 12 of the Double-Blind Treatment Period in Interquartile Range of Dyskinesia Score (DK75-DK25) as Assessed by the PKG Wearable Device	The PKG wearable device is an innovative mobile health technology that provides continuous, objective, ambulatory assessment of the symptoms of PD including tremor, bradykinesia, dyskinesia, and daytime somnolence. For each participant, the PKG watch collected data continuously and an algorithm calculated a dyskinesia score every 2 minutes between 9am-6pm across multiple days. Among these scores for this participant at this visit, the median of all the score values is defined as DK50 (there is no prespecified range of scores). DK75-DK25 is the difference between the third quartile (DK75) and first quartile (DK25) dyskinesia scores, and this interquartile range is a measure of variability of dyskinesia. A higher score indicates a higher degree of variability in dyskinesia scores. The DK75 and DK25 scores for all participants across all visits were then analyzed with mixed-effect model for repeated measures (MMRM) and the LS mean (model-based mean) was obtained from the model.	Baseline (Week 0) up to Week 12 of the double-blind treatment period
Secondary	Number of Participants With Irritation Grade Numeric Grade >= 5 or Letter Grade >= D on the Infusion Site Irritation Scale Across All Study Post-Baseline Visits	The investigator or qualified designee evaluated the infusion site area (abdomen). A 2-part (numeric and letter grading) evaluation scale was used to assess irritation. Irritation - Numeric Grades: 0 = No evidence of irritation; 1 = Minimal erythema, barely perceptible; 2 = Moderate erythema, readily visible; or minimal edema, or minimal papular response; 3 = Erythema and papules; 4 = Definite edema; 5 = Erythema, edema, and papules; 6 = Vesicular eruption; 7 = Strong reaction spreading beyond the test site. Irritation - Letter Grades: A = No finding; B = Slight glazed appearance; C = Marked glazing; D = Glazing with peeling and cracking; E = Glazing with fissures; F = Film of dried serous exudates covering all or portion of the patch site; G = Small petechial erosions and/or scabs.	Day 2 up to Week 12 of the double-blind treatment period plus 30 days
Secondary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the Oral LD/CD Stabilization Period	An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. An AE, whether associated with study drug or not, meeting any of the following criteria is considered a serious AE (SAE): results in death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent a serious outcome. The severity of each AE is rated as mild, moderate, or severe, and having either a reasonable possibility or no reasonable possibility of relationship to study drug. Events were considered treatment emergent if they arose after the first dose of study drug.	From first dose of stabilization period treatment up to the first dose of the double-blind treatment period
Secondary	Number of Participants With TEAEs During the Double-Blind Treatment Period	An AE is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. An AE, whether associated with study drug or not, meeting any of the following criteria is considered an SAE: results in death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent a serious outcome. The severity of each AE is rated as mild, moderate, or severe, and having either a reasonable possibility or no reasonable possibility of relationship to study drug. Adverse events of special interest include polyneuropathy, weight loss, somnolence, hallucinations/psychosis. Events were considered treatment emergent if they arose after the first dose of study drug.	From first dose of double-blind treatment up to Week 12 of the double-blind treatment period plus 30 days
Secondary	Number of Participants With Potentially Clinically Significant Changes From Baseline in Hematology, Chemistry, Urinalysis, Special Laboratory Parameters, Vital Signs, and Electrocardiograms (ECGs)	Measures analyzed for prespecified potentially clinically significant criteria: hematology (hematocrit, hemoglobin, red blood cells, white blood cells, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular hemoglobin, mean corpuscular volume concentration, prothrombin time, activated partial thromboplastin time), laboratory (blood urea nitrogen, creatinine, creatine phosphokinase, bilirubin, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, phosphorus, uric acid, total protein, albumin, glucose, sodium bicarbonate, chloride, triglycerides, cholesterol, magnesium), special lab criteria (vitamin B12, vitamin B6, folate, homocysteine, methylmalonic acid), vital signs (diastolic and systolic blood pressure, pulse rate), ECG (heart rate, PR, and QTcF interval), urinalysis (specific gravity, ketones, pH, protein, glucose, blood, bilirubin).	Screening up to Week 12 of the double-blind treatment period
Secondary	Number of Participants With Affirmative Responses on the Columbia-Suicide Severity Rating Scale (C-SSRS) Across All Study Post-Baseline Visits During the Double-Blind Treatment Period	The C-SSRS is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.	Screening up to Week 12 of the double-blind treatment period
Secondary	Number of Participants With a Subscore > 5 For Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Ration Scale (QUIP-RS) at Any Time During the Double-Blind Treatment Period	The QUIP-RS measures the severity of symptoms and support a diagnosis of impulse control disorders and related disorders in PD. QUIP-RS subscores include gambling (score 0 to 16), sex (score 0 to 16), buying (score 0 to 16), eating (score 0 to 16), hobbyism-punding (score 0 to 32), and PD medication use (score 0 to 16). Higher scores represent a worse outcome.	Baseline (Week 0) up to Week 12 of the double-blind treatment period